![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANO4 |
Gene summary for ANO4 |
![]() |
Gene information | Species | Human | Gene symbol | ANO4 | Gene ID | 121601 |
Gene name | anoctamin 4 | |
Gene Alias | TMEM16D | |
Cytomap | 12q23.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B7Z9Z0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
121601 | ANO4 | ATC13 | Human | Thyroid | ATC | 3.04e-38 | 6.37e-01 | 0.34 |
121601 | ANO4 | ATC5 | Human | Thyroid | ATC | 2.12e-37 | 6.83e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANO4 | SNV | Missense_Mutation | novel | c.964N>C | p.Glu322Gln | p.E322Q | Q32M45 | protein_coding | tolerated(0.43) | benign(0.062) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
ANO4 | SNV | Missense_Mutation | rs141487719 | c.2392N>T | p.Arg798Cys | p.R798C | Q32M45 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A5ZW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
ANO4 | SNV | Missense_Mutation | novel | c.2131N>T | p.Asp711Tyr | p.D711Y | Q32M45 | protein_coding | tolerated(0.16) | probably_damaging(0.982) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANO4 | SNV | Missense_Mutation | c.2338N>A | p.Leu780Ile | p.L780I | Q32M45 | protein_coding | tolerated(0.09) | possibly_damaging(0.462) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ANO4 | SNV | Missense_Mutation | novel | c.2674N>A | p.Glu892Lys | p.E892K | Q32M45 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANO4 | SNV | Missense_Mutation | c.880N>T | p.Ala294Ser | p.A294S | Q32M45 | protein_coding | deleterious(0.01) | benign(0.259) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
ANO4 | SNV | Missense_Mutation | c.2356N>A | p.Ala786Thr | p.A786T | Q32M45 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-BH-A0W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR | |
ANO4 | SNV | Missense_Mutation | c.1922N>C | p.Gly641Ala | p.G641A | Q32M45 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ANO4 | SNV | Missense_Mutation | c.1066T>C | p.Trp356Arg | p.W356R | Q32M45 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
ANO4 | SNV | Missense_Mutation | novel | c.2242N>A | p.Asp748Asn | p.D748N | Q32M45 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |